In a surprise move, Shire Pharmaceuticals has ended its bid for FDA approval for its Replagal biologic for treating Fabry disease, a rare, but life-threatening genetic disorder. The move comes less than two months after the FDA approved a manufacturing plant operated by Genzyme, which experienced shortages of its own medication for the past two years and is now trying to restoring regular supplies.

pubblicato il: 15/03/2012 - 13:23